reason report
first fda approv biosimilar neulasta goe mylan
bottom line today fda approv mylan/biocon fulphila
first biosimilar mp neulasta gain approv
us compani anticip launch fulphila come
week updat sale number biosimilar neulasta
us approv well incorpor assumpt
improv initi biosimilar uptak base chang took
effect begin year assum revenu
higher previou estim
respect increas ep
ep price target
continu like diversifi product geograph portfolio
pipelin opportun difficult-to-manufactur limit competit
high brand valu market gener advair potenti later
first-to-market statu along favor reimburs could
drive meaning sale near-term effort improv
biosimilar uptak begin year drug price
program biosimilar grant pass-through statu
reimburs averag sell price asp plu equal asp
biosimilar plu asp brand period
year brand get reduc medicar payment asp
minu believ key financi incent
rapid uptak biosimilar hospit
believ constitut brand sale base coheru nr
commentari top could limit competit
environ time coheru goal date novemb
potenti competitor would amneal op /adello
file sometim year sandoz file given estim
approv timelin difficulti first pass approv product
would appli amneal/adello believ coheru
could biosimilar market least
lower sale outer year favor reimburs
window expir addit competit entrant
note biosimilar approv get year window
favor reimburs vs brand therefor
window close impli sometim
reimburs biosimilar revert par brand
asp minu biosimilar still favor
reimburs period would get asp plu assum addit
ev/ebitda multipl
net debt total capit
gener
compani inform leerink partner llc research
revenu
pleas refer page import disclosur price chart analyst certif
biosimilar entrant like amneal/adello sandoz come
would put unfavor reimburs posit
within set period model
attribut minim revenu set time
lower biosimilar neulasta sale
reflect dynam one could argu
outer year would disadvantag
biosimilar term reimburs set could also
impact share set hospit would like
purchas exclus one biosimilar manufactur need
howev difficult assess effect could therefor
simplic assum biosimilar manufactur split
market equal spillov effect unfavor reimburs
may off-set longest durat biosimilar
place outperform rate share base strong pipelin biosimilar
durabl ou busi growth off-set continu us base busi
gener eros support revenu growth potenti near-term
upsid consensu number limit competit copaxon advair though
difficult high visibl insulin/biosimilar growth driver could
expand multipl rel peer strong balanc sheet allow
share buy-back smaller bolt-on acquisit expand geograph and/or therapeut
use weight averag ev/ebitda multipl ebitda deriv
price target per share
gener advair may get approv commerci uptak biosimilar may take longer
anticip growth ou market may slower expect market penetr
gener copaxon may improv
number except per share data
net debt ebitda ratio
number except per share data
number except per share data
assum ftf product
gleevec approv launch
restasi assum launch pend approv
lialda launch jan zydu day exclus expir pend approv
advair assum get approv
cubicin assum get approv
ulor settlement june tent approv
treanda assum settlement par ftf date pend approv
norvir/kaletra assum patent expir jan tent approv
tarceva undisclos settlement assum month last patent approv
sutent lost feb patent tent approv
jevtana assum patent expiri pend approv
brilinta assum jul patent expiri pend approv
brevibloc undisclos settlement assum month last patent expiri approv
number except per share data
januvia franchis assum compound patent tent approv
vimpat lost patent expir pend approv
banzel settlement may approv
onglyza franchis lost jul patent pend approv
vyvans lost feb patent tent approv
assum ftf pipelin sub-tot
number except per share data
insulin collabor biocon
biosimilar collabor biocon momenta
eylea phase initi us patent protect
number except per share data
number except per share data
number except per share data
number except per share data
prepaid expens current
current portion ltd
number except per share data
adjust reconcil ni net cash oper
litig settlement conting net
loss acquisition-rel foreign currenc deriv
loss equiti method invest
write financ fee
decreas increas work capit
paid acquisit net
purchas properti plant equip capital-expenditure
payment product right net
paid meda uncondit defer payment
settlement acquisition-rel foreign currenc deriv
proce sale asset subsidiari
purchas market secur
chang restrict cash
proce sale market securitin
net invest
payment financ fee
proce convert note hedg
proce issuance/ purchas ordinari share net
proce exercis stock option
tax paid relat net share settlement equiti award
acquisit non-controlling interest
net financ
effect cash chang exchang rate
net chang equival
